Niki Palmetto

Quantitative Safety & Epidemiology, Patient Safety & Pharmacovigilance, Development, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA

Poster(s):

• (028) Results from an analysis of data from the US SEER registries to estimate the prevalence of gastroenteropancreatic neuroendocrine tumors in the US, in the context of limited available evidence for regulatory discussions
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (BSPOT35) Leverage of an EHR Database to Estimate Prevalence and Incidence of Lymphatic Malformations (a Rare Disease) in the UK
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST